表示活动产品，点击可查看产品信息
FACS认证的免疫检查点蛋白Protocol免费申请
近年来，免疫检查点蛋白因其在肿瘤发生和发展中的重要作用备受关注。通常，肿瘤细胞可以通过阻断免疫检查点通路来逃脱免疫系统的攻击。因此，研究者相信调控免疫检查点通路可使免疫系统重新激活，从而对抗肿瘤。值得一提的是，anti-CTLA4和anti-PD1单克隆药物已经在多种恶性肿瘤的临床试验中展现出不错的疗效，同时研究人员也在开发针对其他检查点蛋白的抗体药物，从而找到更好的治疗肿瘤的方法。
为了支持上述研究，ACROBiosystems开发了一系列免疫检查点蛋白产品，涵盖了已知的绝大部分免疫检查点分子。客户可以选择标记的，非标记的，不同标签的（如Fc, His, Mouse Fc, Strep）或者无标签的蛋白产品。除了常用的人种属之外，我们还为动物实验提供小鼠、大鼠、兔、恒河猴（rhesus macaque）和食蟹猴（cynomolgus）的蛋白。
标准规范的生产工艺加上严格的质量控制，保证了我们所有产品的高质量，我们的免疫检查点蛋白产品具有高纯度、高生物活性并且性能稳定。
Figure 2. The purity of ACROBiosystems Human LAG-3, Fc Tag (Cat. No. LA3-H5255) is determined to be greater than 94%(A), while the purity of a comparable product from company R is determined to be greater than 76%(B).
The tumor necrosis factor (TNF) superfamily contains 19 ligands and 29 receptors, including TNFSF4 (OX40 Ligand), TNFSF7(CD27 Ligand), TNFSF5(CD40 Ligand), among others. The endogenous TNF superfamily ligands often form trimer(Russell et al., 2018)
Figure 3. The purity of Human CD27 Ligand, His,Flag Tag (active trimer) (MALS verified) (Cat. No. CDL-H52Da) was more than 95% in HP-SEC, and around 55-70 kDa verified by SEC-MALS.
我们的免疫检查点蛋白及其配体或受体的生物活性在一系列测定中得到验证，包括ELISA(图4,5和图10），SPR（图6和图11），和BLI&FACS（图7），包括结合实验（图6和图10）和/或中和实验（图7和图11）。
CD47-SIRPalpha这个通路在吞噬作用中起抑制作用（Liu等，2017）。因此，通过单克隆抗体阻断SIRPalpha-CD47这个通路（图7）可以有效治疗癌症（Huang等，2017）。
ACROBiosystems提供一组独特的CD47相关产品，包括生物素化的蛋白，用于快速高通量筛选。除了常用的人种属之外，我们还为动物实验提供小鼠、大鼠、兔、恒河猴（rhesus macaque）和食蟹猴（cynomolgus）的CD47和SIRPα蛋白。
Figure 4. Immobilized Human SIRP alpha, Fc Tag (Cat. No. SIA-H5251) at 2 μg/mL (100 μL/well) can bind Unconjugated Human CD47, His,Avitag (Cat. No. CD7-HA2E9) with a linear range of 2-13 ng/mL (QC tested).
Figure 5. Immobilized Anti-CD47 MAb, Human IgG4 at 2 μg/mL (100 μL/well) can bind Unconjugated Human CD47, His,Avitag (Cat. No. CD7-HA2E9) with a linear range of 0.05-2 ng/mL (QC tested).
Figure 6. Anti-Human CD47 MAb (Human IgG4) captured on CM5 chip via Anti-Human IgG Fc antibodies surface, can bind Human CD47, His Tag (Cat. No. CD7-H5227) with an affinity constant of 1.66 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
Figure 7. Anti-Human CD47 MAb (Human IgG4) captured on CM5 chip via Anti-Human IgG Fc antibodies surface, can bind Human CD47, Figure 7. Loaded Anti-Human CD47 MAb (Human IgG4) on AHC Biosensor, can bind Human CD47, His Tag (Cat. No. CD7-H5227) with an affinity constant of 6.18 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Figure 8. FACS assay shows that recombinant Human SIRP alpha, His Tag (HPLC-verified) (Cat. No. SIA-H5225) can bind to Jurkat cell expressing CD47. The concentration of SIRP alpha used is 1 ug/ml (Routinely tested).
Figure 9. FACS analysis shows that the binding of Human SIRP alpha, His Tag (HPLC-verified) (Cat. No. SIA-H5225) to Jurkat expressing CD47 was inhibited by increasing concentration of neutralizing anti-CD47 antibody. The concentration of SIRP alpha used is 1 ug/ml. IC50=0.2257 ug/ml (Routinely tested).
TIGIT-CD155之间的相互作用会引发黑素瘤的免疫抑制机制（Mahnke和Enk，2016）。因此，通过单克隆抗体阻断TIGIT-CD155的相互作用（图11）可以有效治疗癌症。
ACROBiosystems开发了一系列TIGIT通路上的蛋白，包括TIGIT，CD155，DNAM-1，CD96，Nectin1（CD111），Nectin2（CD112），PVRIG（CD112R），Nectin3（CD113），Nectin4。除了常用的his，Fc和mouse Fcb标签的产品外，我们还有生物素标记的产品。除了常用的人种属之外，我们还为动物实验提供小鼠、大鼠、兔、恒河猴（rhesus macaque）和食蟹猴（cynomolgus）的TIGIT通路上的蛋白。
Figure 10. Immobilized Human TIGIT, His Tag (Cat. No. TIT-H52H3) at 2μg/mL (100 μL/well) can bind Human CD155, Fc Tag (Cat. No. CD5-H5251) with a linear range of 8-128 ng/mL (QC tested).
Figure 11. Anti-Human TIGIT MAb (Mouse IgG1) captured on CM5 chip via Anti-Mouse antibodies surface, can bind Human TIGIT, His Tag (Cat. No. TIT-H52H3) with an affinity constant of 3.93 nM as determined in a SPR assay (Biacore T200) (Routinely tested)
Figure 12. FACS assay shows that Biotinylated Human CD155, Fc Tag, Avi Tag (Cat. No. CD5-H82F6) can bind to 293T cell overexpressing human TIGIT. The concentration of CD155 is 1 μg/ml (Routinely tested).
Figure 13. FACS analysis shows that the binding of Biotinylated Human CD155, Fc Tag, Avi Tag (Cat. No. CD5-H82F6) to 293T overexpressing TIGIT was inhibited by increasing concentration of neutralizing Anti-Human TIGIT MAb. The concentration of CD155 used is 1 μg/ml. The IC50 is 0.201 μg/ml (Routinely tested).
| Molecule | sign | Species | Tag |
|
|---|---|---|---|---|
| B7-2 | CD6-H5257 | Human | C-Fc |
Request FACS Protocol
|
| CD6-H82F5 | Human | C-Fc & C-Avi |
Request FACS Protocol
|
|
| CD155 | CD5-H5251 | Human | C-Fc |
Request FACS Protocol
|
| CD5-H82F6 | Human | C-Fc & C-Avi |
Request FACS Protocol
|
|
| CD5-H5254 | Human | C-mFc |
Request FACS Protocol
|
|
| CD40 | CD0-H5253 | Human | C-Fc |
Request FACS Protocol
|
| DNAM-1 | DN1-H52H6 | Human | C-His |
Request FACS Protocol
|
| DN1-H5257 | Human | C-Fc |
Request FACS Protocol
|
|
| DN1-H82F9 | Human | C-Fc & C-Avi |
Request FACS Protocol
|
|
| LAG-3 | LA3-C5252 | Cynomolgus | C-Fc |
Request FACS Protocol
|
| LA3-H52Aa | Human | C-mFc |
Request FACS Protocol
|
|
| LA3-H82F3 | Human | C-mFc & C-Avi |
Request FACS Protocol
|
|
| OX40 | OX0-H5224 | Human | C-His |
Request FACS Protocol
|
| OX0-H5255 | Human | C-Fc |
Request FACS Protocol
|
|
| OX0-H82F7 | Human | C-Fc & C-Avi |
Request FACS Protocol
|
|
| TN4-H82E4 | Human | C-Avi & C-His |
Request FACS Protocol
|
|
| OX0-H5252 | Human | C-mFc |
Request FACS Protocol
|
|
| OX40 Ligand | OXL-H52Q8 | Human | N-His |
Request FACS Protocol
|
| OXL-H526x | Human | N-Fc |
Request FACS Protocol
|
|
| OXL-H5250 | Human | C-mFc |
Request FACS Protocol
|
|
| PD-1 | PD1-H5257 | Human | C-Fc |
Request FACS Protocol
|
| PD1-H82F2 | Human | C-Fc & C-Avi & C-His |
Request FACS Protocol
|
|
| PD-L1 | PD1-H5258 | Human | C-Fc |
Request FACS Protocol
|
| PD1-H82F3 | Human | C-Fc & C-Avi & C-His |
Request FACS Protocol
|
|
| PD1-H52A3 | Human | C-mFc |
Request FACS Protocol
|
|
| PD-L2 | PD2-H5251 | Human | C-Fc |
Request FACS Protocol
|
| PD2-H52A5 | Human | C-mFc |
Request FACS Protocol
|
|
| SIRP alpha | SIA-H5225 | Human | C-His |
Request FACS Protocol
|
| SIA-H5251 | Human | C-Fc |
Request FACS Protocol
|
|
| SIA-H52A8 | Human | C-mFc |
Request FACS Protocol
|
|
| SIA-H5351 | Human | C-Fc |
Request FACS Protocol
|
|
| CDA-H82F2 | Human | C-Fc & C-Avi |
Request FACS Protocol
|
|
| TIGIT | TIT-H5254 | Human | C-Fc |
Request FACS Protocol
|
| TIT-H52H3 | Human | C-His |
Request FACS Protocol
|
|
| TIT-H82F1 | Human | C-Fc & C-Avi |
Request FACS Protocol
|
|
| TIT-H82E5 | Human | C-Avi & C-His |
Request FACS Protocol
|
|
| TIT-H5253 | Human | C-mFc |
Request FACS Protocol
|
ACROBiosystems开发了各种生物素标记的免疫检查点蛋白，具有低背景，高特异性，高生物活性和低批间差的特点。这些产品可用于ELISA，AlphaLISA，SPR，FACS等实验。
ACROBiosystems为纳米抗体研究开发了一系列Llama IgG Fc标签的免疫检查点蛋白，具有增强靶点蛋白免疫原性，标签免疫原性低，半衰期长，稳定性好，低内毒素（0.01 EU /μg），高纯度和高活性的特点。
| LILRA1 | LILRA2 | LILRA3 | LILRA5 | LILRA6 |
| LILRB1 | LILRB2 | LILRB3 | LILRB4 | LILRB5 |
| LAIR-1 | LAIR-2 | LILRA3 | LILRA5 | LILRA6 |
| SLAMF1 | SLAMF2(CD48) | SLAMF3(CD229) | SLAMF4(2B4) | SLAMF5(CD84) |
| SLAMF5(NTB-A) | SLAMF7 | SLAMF9(CD2F-10) |
|
|
| BTN1A1 | BTN3A1 | BTN3A2 | BTN3A3 | BTNL3 |
| BTNL9 |
|
|
|
|
我们还开发了PD1-PD-L1抑制剂筛选测定试剂盒（Cat. No. EP-101），可以快速并且高通量地筛选PD-1-PD-L1通路的抑制性抗体或小分子。
